Crotedumab

Drug Profile

Crotedumab

Alternative Names: REGN-1193

Latest Information Update: 03 Jun 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Regeneron Pharmaceuticals; Sanofi
  • Developer Regeneron Pharmaceuticals
  • Class Antihyperglycaemics; Monoclonal antibodies
  • Mechanism of Action Glucagon receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 10 May 2016 Regeneron terminates a phase I trial in Type-2 diabetes mellitus in USA (NCT02284425)
  • 05 Feb 2016 Regeneron completes a phase I trial in Type-2 diabetes mellitus (In volunteers) in USA (NCT01933763)
  • 01 Oct 2014 Phase-I clinical trials in Type-2 diabetes mellitus in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top